Mandate

Vinge advises FSN Capital L.P. II et al. on divestment of the CTEK/Creator Group

June 09, 2011

Vinge is advising FSN Capital L.P. II et al. in connection with the divestment of the CTEK/Creator Group to Altor Fund III.

The CTEK/Creator group is the world’s premier manufacturer of advanced battery chargers, sold under inter alia the "CTEK" brand, and a provider of consulting services related to product development under the “Creator” brand. CTEK is, in addition to sales under its own brand, delivering battery chargers to well renowned brands such as Rolls Royce, Ferrari, Porsche, Bentley, Mercedes-Benz, BMW, Lexus, Lamborghini, Alfa Romeo, Audi, Corvette, Maserati, Scania and Yamaha.

Since the investment by FSN Capital L.P. II in April 2008, CTEK has experienced largely increased sales volumes as well as a largely increased EBITDA despite having made significant investments in sales & marketing, R&D and the overall organization.

Closing of the transaction is subject to applicable competition law approvals.

The Vinge team advising FSN Capital L.P. et al. includes partners Bo Adrianzon and Johan Göthberg and inter alia associates Johan Steen, Carolina Walther and Ulrich Ziche.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025